Management of cancer anorexia/cachexia

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Cancer anorexia/cachexia is a common clinical problem that substantially impacts upon the quality of life and survival of affected patients. Extensive investigations have not supported the use of either enteral or paternal hyperalimentation for such patients. Despite positive pilot trial reports, large randomized studies have been unable to demonstrate a clinically defensible role for either pentoxifylline, cyproheptadine, or hydrazine sulfate for patients with anorexia. Multiple placebo-controlled, randomized, double-blind, clinical trials have demonstrated that corticosteroids do have appetite-enhancing properties in patients suffering from cancer anorexia/cachexia, but none of these studies has demonstrated weight gain. In comparison, multiple studies have demonstrated that the progestational agent, megestrol acetate, has both appetite-enhancing and weight-promoting properties.

Original languageEnglish (US)
Pages (from-to)120-122
Number of pages3
JournalSupportive Care in Cancer
Volume3
Issue number2
DOIs
StatePublished - Mar 1995

Fingerprint

Cachexia
Anorexia
hydrazine
Appetite
Neoplasms
Megestrol Acetate
Cyproheptadine
Pentoxifylline
Progestins
Small Intestine
Weight Gain
Adrenal Cortex Hormones
Placebos
Quality of Life
Clinical Trials
Weights and Measures
Survival

Keywords

  • Cancer anorexia
  • Cancer cachexia
  • Corticosteroids
  • Megestrol acetate

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Management of cancer anorexia/cachexia. / Loprinzi, Charles Lawrence.

In: Supportive Care in Cancer, Vol. 3, No. 2, 03.1995, p. 120-122.

Research output: Contribution to journalArticle

@article{161cc5c3737d4ca1af9c1dc29fb397e7,
title = "Management of cancer anorexia/cachexia",
abstract = "Cancer anorexia/cachexia is a common clinical problem that substantially impacts upon the quality of life and survival of affected patients. Extensive investigations have not supported the use of either enteral or paternal hyperalimentation for such patients. Despite positive pilot trial reports, large randomized studies have been unable to demonstrate a clinically defensible role for either pentoxifylline, cyproheptadine, or hydrazine sulfate for patients with anorexia. Multiple placebo-controlled, randomized, double-blind, clinical trials have demonstrated that corticosteroids do have appetite-enhancing properties in patients suffering from cancer anorexia/cachexia, but none of these studies has demonstrated weight gain. In comparison, multiple studies have demonstrated that the progestational agent, megestrol acetate, has both appetite-enhancing and weight-promoting properties.",
keywords = "Cancer anorexia, Cancer cachexia, Corticosteroids, Megestrol acetate",
author = "Loprinzi, {Charles Lawrence}",
year = "1995",
month = "3",
doi = "10.1007/BF00365851",
language = "English (US)",
volume = "3",
pages = "120--122",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Management of cancer anorexia/cachexia

AU - Loprinzi, Charles Lawrence

PY - 1995/3

Y1 - 1995/3

N2 - Cancer anorexia/cachexia is a common clinical problem that substantially impacts upon the quality of life and survival of affected patients. Extensive investigations have not supported the use of either enteral or paternal hyperalimentation for such patients. Despite positive pilot trial reports, large randomized studies have been unable to demonstrate a clinically defensible role for either pentoxifylline, cyproheptadine, or hydrazine sulfate for patients with anorexia. Multiple placebo-controlled, randomized, double-blind, clinical trials have demonstrated that corticosteroids do have appetite-enhancing properties in patients suffering from cancer anorexia/cachexia, but none of these studies has demonstrated weight gain. In comparison, multiple studies have demonstrated that the progestational agent, megestrol acetate, has both appetite-enhancing and weight-promoting properties.

AB - Cancer anorexia/cachexia is a common clinical problem that substantially impacts upon the quality of life and survival of affected patients. Extensive investigations have not supported the use of either enteral or paternal hyperalimentation for such patients. Despite positive pilot trial reports, large randomized studies have been unable to demonstrate a clinically defensible role for either pentoxifylline, cyproheptadine, or hydrazine sulfate for patients with anorexia. Multiple placebo-controlled, randomized, double-blind, clinical trials have demonstrated that corticosteroids do have appetite-enhancing properties in patients suffering from cancer anorexia/cachexia, but none of these studies has demonstrated weight gain. In comparison, multiple studies have demonstrated that the progestational agent, megestrol acetate, has both appetite-enhancing and weight-promoting properties.

KW - Cancer anorexia

KW - Cancer cachexia

KW - Corticosteroids

KW - Megestrol acetate

UR - http://www.scopus.com/inward/record.url?scp=0029270564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029270564&partnerID=8YFLogxK

U2 - 10.1007/BF00365851

DO - 10.1007/BF00365851

M3 - Article

C2 - 7773579

AN - SCOPUS:0029270564

VL - 3

SP - 120

EP - 122

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 2

ER -